Login / Signup

PIKing up and AKTing on resistance mutations in osimertinib-treated EGFR-mutated NSCLC.

Natalie I VokesXiuning LiTimothy Anthony Yap
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these mutations decreased osimertinib sensitivity in EGFR-mutated NSCLC. The AKT inhibitor capivasertib was found to overcome this resistance, providing important rationale for the development of AKT inhibitors in NSCLC.
Keyphrases
  • small cell lung cancer
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • brain metastases
  • signaling pathway
  • cell proliferation
  • tyrosine kinase
  • clinical trial